Indications of Interest:
We are interested in new therapies for multiple myeloma; other hematological malignancies; solid tumors—gastrointestinal (GI), genitourinary (GU), lung and breast cancers; novel targeted payload approaches—antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), CD3 engagers, etc.; novel immune-oncology approaches and novel approaches targeting protein homeostasis.